159 related articles for article (PubMed ID: 35169092)
21. Gliomas in children and adolescents: investigation of molecular alterations with a potential prognostic and therapeutic impact.
Cabral de Carvalho Corrêa D; Tesser-Gamba F; Dias Oliveira I; Saba da Silva N; Capellano AM; de Seixas Alves MT; Dastoli PA; Cavalheiro S; Caminada de Toledo SR
J Cancer Res Clin Oncol; 2022 Jan; 148(1):107-119. PubMed ID: 34626238
[TBL] [Abstract][Full Text] [Related]
22. Pediatric brain tumors: the era of molecular diagnostics, targeted and immune-based therapeutics, and a focus on long term neurologic sequelae.
Plant-Fox AS; O'Halloran K; Goldman S
Curr Probl Cancer; 2021 Aug; 45(4):100777. PubMed ID: 34303558
[TBL] [Abstract][Full Text] [Related]
23. To BRAF or not to BRAF: is that even a question anymore?
Horbinski C
J Neuropathol Exp Neurol; 2013 Jan; 72(1):2-7. PubMed ID: 23242278
[TBL] [Abstract][Full Text] [Related]
24. Multiplex Detection of Pediatric Low-Grade Glioma Signature Fusion Transcripts and Duplications Using the NanoString nCounter System.
Ryall S; Arnoldo A; Krishnatry R; Mistry M; Khor K; Sheth J; Ling C; Leung S; Zapotocky M; Guerreiro Stucklin A; Lassaletta A; Shago M; Tabori U; Hawkins CE
J Neuropathol Exp Neurol; 2017 Jul; 76(7):562-570. PubMed ID: 28863456
[TBL] [Abstract][Full Text] [Related]
25. Molecular markers and targeted therapy in pediatric low-grade glioma.
de Blank P; Fouladi M; Huse JT
J Neurooncol; 2020 Oct; 150(1):5-15. PubMed ID: 32399739
[TBL] [Abstract][Full Text] [Related]
26. Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor.
Kiehna EN; Arnush MR; Tamrazi B; Cotter JA; Hawes D; Robison NJ; Fong CY; Estrine DB; Han JH; Biegel JA
J Neurosurg Pediatr; 2017 Jul; 20(1):51-55. PubMed ID: 28387643
[TBL] [Abstract][Full Text] [Related]
27. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma.
Mistry M; Zhukova N; Merico D; Rakopoulos P; Krishnatry R; Shago M; Stavropoulos J; Alon N; Pole JD; Ray PN; Navickiene V; Mangerel J; Remke M; Buczkowicz P; Ramaswamy V; Guerreiro Stucklin A; Li M; Young EJ; Zhang C; Castelo-Branco P; Bakry D; Laughlin S; Shlien A; Chan J; Ligon KL; Rutka JT; Dirks PB; Taylor MD; Greenberg M; Malkin D; Huang A; Bouffet E; Hawkins CE; Tabori U
J Clin Oncol; 2015 Mar; 33(9):1015-22. PubMed ID: 25667294
[TBL] [Abstract][Full Text] [Related]
28. Infant-Type Hemispheric Glioma in a Chinese Girl: A Newly Defined Entity.
Fang Y; Wang YZ; Wei X; Li SM; Chen L
Fetal Pediatr Pathol; 2023 Feb; 42(1):114-122. PubMed ID: 35404193
[TBL] [Abstract][Full Text] [Related]
29. Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation.
Dodgshun AJ; SantaCruz N; Hwang J; Ramkissoon SH; Malkin H; Bergthold G; Manley P; Chi S; MacGregor D; Goumnerova L; Sullivan M; Ligon K; Beroukhim R; Herrington B; Kieran MW; Hansford JR; Bandopadhayay P
J Neurooncol; 2016 Jun; 128(2):293-302. PubMed ID: 26994902
[TBL] [Abstract][Full Text] [Related]
30. LOGGIC Core BioClinical Data Bank: Added clinical value of RNA-Seq in an international molecular diagnostic registry for pediatric low-grade glioma patients.
Hardin EC; Schmid S; Sommerkamp A; Bodden C; Heipertz AE; Sievers P; Wittmann A; Milde T; Pfister SM; von Deimling A; Horn S; Herz NA; Simon M; Perera AA; Azizi A; Cruz O; Curry S; Van Damme A; Garami M; Hargrave D; Kattamis A; Kotnik BF; Lähteenmäki P; Scheinemann K; Schouten-van Meeteren AYN; Sehested A; Viscardi E; Wormdal OM; Zapotocky M; Ziegler DS; Koch A; Hernáiz Driever P; Witt O; Capper D; Sahm F; Jones DTW; van Tilburg CM
Neuro Oncol; 2023 Nov; 25(11):2087-2097. PubMed ID: 37075810
[TBL] [Abstract][Full Text] [Related]
31. Molecular genetics of ependymomas and pediatric diffuse gliomas: a short review.
Nobusawa S; Hirato J; Yokoo H
Brain Tumor Pathol; 2014 Oct; 31(4):229-33. PubMed ID: 25182241
[TBL] [Abstract][Full Text] [Related]
32. EANO guideline on rational molecular testing of gliomas, glioneuronal, and neuronal tumors in adults for targeted therapy selection.
Capper D; Reifenberger G; French PJ; Schweizer L; Weller M; Touat M; Niclou SP; Euskirchen P; Haberler C; Hegi ME; Brandner S; Le Rhun E; Rudà R; Sanson M; Tabatabai G; Sahm F; Wen PY; Wesseling P; Preusser M; van den Bent MJ
Neuro Oncol; 2023 May; 25(5):813-826. PubMed ID: 36632791
[TBL] [Abstract][Full Text] [Related]
33. Genomic and epigenomic re-categorization of congenital glioblastoma and desmoplastic infantile ganglioglioma.
Gilani A; Siddiq Z; Kissell E; Kasson J; Kleinschmidt-DeMasters BK
Childs Nerv Syst; 2023 Jul; 39(7):1861-1868. PubMed ID: 36707425
[TBL] [Abstract][Full Text] [Related]
34. Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy.
Kline CN; Joseph NM; Grenert JP; van Ziffle J; Talevich E; Onodera C; Aboian M; Cha S; Raleigh DR; Braunstein S; Torkildson J; Samuel D; Bloomer M; Campomanes AGA; Banerjee A; Butowski N; Raffel C; Tihan T; Bollen AW; Phillips JJ; Korn WM; Yeh I; Bastian BC; Gupta N; Mueller S; Perry A; Nicolaides T; Solomon DA
Neuro Oncol; 2017 May; 19(5):699-709. PubMed ID: 28453743
[TBL] [Abstract][Full Text] [Related]
35. Radiological and Immunostaining Characteristics of H3.3 G34R-Mutant Glioma: A Report of 3 Cases and Review of the Literature.
Onishi S; Amatya VJ; Karlowee V; Takeshima Y; Sugiyama K; Kurisu K; Yamasaki F
Pediatr Neurosurg; 2020; 55(5):319-325. PubMed ID: 33227796
[TBL] [Abstract][Full Text] [Related]
36. A Cell-Based MAPK Reporter Assay Reveals Synergistic MAPK Pathway Activity Suppression by MAPK Inhibitor Combination in
Usta D; Sigaud R; Buhl JL; Selt F; Marquardt V; Pauck D; Jansen J; Pusch S; Ecker J; Hielscher T; Vollmer J; Sommerkamp AC; Rubner T; Hargrave D; van Tilburg CM; Pfister SM; Jones DTW; Remke M; Brummer T; Witt O; Milde T
Mol Cancer Ther; 2020 Aug; 19(8):1736-1750. PubMed ID: 32451331
[TBL] [Abstract][Full Text] [Related]
37. Mutations in the RAS/MAPK Pathway Drive Replication Repair-Deficient Hypermutated Tumors and Confer Sensitivity to MEK Inhibition.
Campbell BB; Galati MA; Stone SC; Riemenschneider AN; Edwards M; Sudhaman S; Siddaway R; Komosa M; Nunes NM; Nobre L; Morrissy AS; Zatzman M; Zapotocky M; Joksimovic L; Kalimuthu SN; Samuel D; Mason G; Bouffet E; Morgenstern DA; Aronson M; Durno C; Malkin D; Maris JM; Taylor MD; Shlien A; Pugh TJ; Ohashi PS; Hawkins CE; Tabori U
Cancer Discov; 2021 Jun; 11(6):1454-1467. PubMed ID: 33563663
[TBL] [Abstract][Full Text] [Related]
38. EGFR blockade prevents glioma escape from BRAFV600E targeted therapy.
Yao TW; Zhang J; Prados M; Weiss WA; James CD; Nicolaides T
Oncotarget; 2015 Sep; 6(26):21993-2005. PubMed ID: 26023796
[TBL] [Abstract][Full Text] [Related]
39. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas.
McCord M; Steffens A; Javier R; Kam KL; McCortney K; Horbinski C
Acta Neuropathol Commun; 2020 Feb; 8(1):15. PubMed ID: 32051040
[TBL] [Abstract][Full Text] [Related]
40. Dabrafenib Effective in Pediatric Glioma.
Cancer Discov; 2017 Jan; 7(1):OF5. PubMed ID: 28062673
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
